162 related articles for article (PubMed ID: 38379018)
1. ESR Essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR.
Cannella R; Zins M; Brancatelli G
Eur Radiol; 2024 Apr; 34(4):2127-2139. PubMed ID: 38379018
[TBL] [Abstract][Full Text] [Related]
2. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates.
Jeon SK; Lee JM; Joo I; Yoo J; Park JY
Eur Radiol; 2020 Sep; 30(9):4762-4771. PubMed ID: 32333148
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients.
Park SH; Shim YS; Kim B; Kim SY; Kim YS; Huh J; Park JH; Kim KW; Lee SS
Eur Radiol; 2021 Jul; 31(7):4751-4763. PubMed ID: 33389037
[TBL] [Abstract][Full Text] [Related]
4. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.
Kim TH; Kim SY; Tang A; Lee JM
Clin Mol Hepatol; 2019 Sep; 25(3):245-263. PubMed ID: 30759967
[TBL] [Abstract][Full Text] [Related]
5. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Four Diagnostic Guidelines for Hepatocellular Carcinoma Using Gadoxetic Acid-enhanced Liver MRI.
Yoon JH; Kim YK; Kim JW; Chang W; Choi JI; Park BJ; Choi JY; Kim SS; Park HS; Lee ES; Yu JS; Park SJ; You MW; Lee CH; Lee JM
Radiology; 2024 Apr; 311(1):e233114. PubMed ID: 38563667
[TBL] [Abstract][Full Text] [Related]
7. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
8. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines.
Kim TH; Yoon JH; Lee JM
Korean J Radiol; 2019 Jun; 20(6):863-879. PubMed ID: 31132813
[TBL] [Abstract][Full Text] [Related]
9. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
[TBL] [Abstract][Full Text] [Related]
10. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
[TBL] [Abstract][Full Text] [Related]
13. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
[TBL] [Abstract][Full Text] [Related]
14. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
15. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
16. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
Kang HJ; Lee JM; Yoon JH; Han JK
Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
[TBL] [Abstract][Full Text] [Related]
17. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of the 2018 EASL vs. LI-RADS for Hepatocellular Carcinoma Using CT and MRI: A Systematic Review and Meta-Analysis of Comparative Studies.
Shin J; Lee S; Yoon JK; Roh YH
J Magn Reson Imaging; 2023 Dec; 58(6):1942-1950. PubMed ID: 37010244
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
Santillan C; Fowler K; Kono Y; Chernyak V
Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
[TBL] [Abstract][Full Text] [Related]
20. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
